Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Safety Risk Communication for Medical Products
Overview
Can't attend this course? Join us in 2020: Washington, DC in November!
What you will learn
- Gain the ability to evaluate risk communication approaches across the medicinal product lifecycle in light of scientific ‘good practices’ and emerging evidence.
- Understand the opportunities for enhancing the effectiveness of safety risk communication in light of evolving regulatory expectations.
- Leave with cutting edge, patient-centered solutions for safety risk communication and risk management strategies.
Who should attend?
This program is designed for professionals involved in:
- Drug safety and pharmacovigilance, especially safety evaluation and periodic safety reporting
- Clinical trial design and operation
- Quality systems
- Medical writing
- Regulatory strategy and regulatory affairs
- Regulatory policy
- Labeling operations and label development
- Risk management plan development, and risk minimization program design, implementation and evaluation (including for formal EU Risk Management Plans and US REMS)
- Benefit-risk assessment of medicinal products
Learning objectives
At the conclusion of this course, participants should be able to:
- Identify good practices and principles for designing effective risk communication messages and tools
- Describe the current regulatory expectations regarding safety risk communication across the medicinal product lifecycle
- Recognize the different types of communication challenges associated with medicinal product risks
- Demonstrate an awareness of risk communication as an integral component of therapeutic risk management
- Discuss the role of implementation in the success of risk communication efforts locally, regionally, and globally
- Evaluate risk communication strategies for feasibility, effectiveness, and patient-centeredness
- Name key future trends in safety risk communication